Randomised, placebo-controlled, triple-blind three-period crossover trial (n=40) in healthy men testing whether BI 409306, BI 425809 or lamotrigine reverse ketamine-induced cognitive deficits.
Primary objective is to investigate whether BI 409306, BI 425809 and lamotrigine attenuate ketamine-induced cognitive deficits in healthy male participants.
Randomized, triple-masked, double-dummy three-treatment period crossover with matched placebo; participants receive each treatment in separate periods (total n=40, tablets/film-coated tablets). Cognitive assessments performed after ketamine challenge to measure memory and related outcomes.
Oral lamotrigine tablet as one treatment period in three-period crossover.
Lamotrigine (tablet) as one treatment in crossover; dose not specified in registry fragment.
Oral BI 409306 film-coated tablet as one treatment period in three-period crossover.
BI 409306 (film-coated tablet); dose not specified in registry fragment.
Oral BI 425809 film-coated tablet as one treatment period in three-period crossover.
BI 425809 (film-coated tablet); dose not specified in registry fragment.
Matched placebo tablet used as control in crossover sequences.
Placebo tablet (film-coated).